Skip to main content

Advertisement

SpringerLink
Log in

Rapid decrease of serum alpha-fetoprotein and tumor volume predicts outcome in children with hepatoblastoma treated with neoadjuvant chemotherapy

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Neoadjuvant chemotherapy is given to children with unresectable hepatoblastoma to increase the rate and safety of curative complete surgical resection. Elevated levels of serum alpha-fetoprotein (sAFP) decline with tumor shrinkage. In this single-institution retrospective study, we determined early dynamic changes of sAFP levels and tumor volume in children during therapy for unresectable hepatoblastoma.

Methods

We correlated early dynamic changes of sAFP levels and tumor volume and the sum of the longest primary tumor and measurable metastatic disease diameters as per RECIST 1.1 criteria with patient outcome.

Results

There were 34 patients, 7 of whom died of disease. Patients with ≥ 90% (≥ 1 log10) decrease in sAFP levels after two chemotherapy courses had a better event-free survival (P = 0.039) and overall survival (OS; P = 0.045) than those with < 90% decrease. During this treatment interval, average tumor volume decreased from 481 mL (± 254 mL) to 268 mL (± 258 mL; P < 0.001) which was associated with OS (P = 0.029). Relative change in sAFP levels or tumor volume in between course 2 and pre-surgery or response as per RECIST 1.1 was not associated with OS.

Conclusion

Early decline of sAFP levels and tumor volume, but not response as per RECIST 1.1 may predict survival in children with unresectable hepatoblastoma. This finding could be useful to identify therapy non-responders for whom alternative interventions may be required for cure. Confirmation of the finding using larger patient cohorts will be necessary before this strategy is incorporated into prospective trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Perilongo G, Maibach R, Shafford E et al (2009) Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 361:1662–1670. https://doi.org/10.1056/NEJMoa0810613

    Article  CAS  PubMed  Google Scholar 

  2. von Schweinitz D (2000) Identification of risk groups in hepatoblastoma—another step in optimising therapy. Eur J Cancer Oxf Engl 1990 36:1343–1346

    Google Scholar 

  3. Czauderna P, Otte JB, Aronson DC et al (2005) Guidelines for surgical treatment of hepatoblastoma in the modern era—recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer Oxf Engl 1990 41:1031–1036. https://doi.org/10.1016/j.ejca.2005.02.004

    Article  Google Scholar 

  4. Meyers RL, Maibach R, Hiyama E et al (2017) Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children’s Hepatic tumors International Collaboration. Lancet Oncol 18:122–131. https://doi.org/10.1016/S1470-2045(16)30598-8

    Article  PubMed  Google Scholar 

  5. De Ioris M, Brugieres L, Zimmermann A et al (2008) Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience. Eur J Cancer Oxf Engl 1990 44:545–550. https://doi.org/10.1016/j.ejca.2007.11.022

    Article  CAS  Google Scholar 

  6. Van Tornout JM, Buckley JD, Quinn JJ et al (1997) Timing and magnitude of decline in alpha-fetoprotein levels in treated children with unresectable or metastatic hepatoblastoma are predictors of outcome: a report from the Children’s Cancer Group. J Clin Oncol Off J Am Soc Clin Oncol 15:1190–1197

    Article  Google Scholar 

  7. Lovvorn HN, Ayers D, Zhao Z et al (2010) Defining hepatoblastoma responsiveness to induction therapy as measured by tumor volume and serum alpha-fetoprotein kinetics. J Pediatr Surg 45:121–128. https://doi.org/10.1016/j.jpedsurg.2009.10.023 (discussion 129)

    Article  PubMed  PubMed Central  Google Scholar 

  8. Koh KN, Park M, Kim BE et al (2011) Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma. Pediatr Blood Cancer 57:554–560. https://doi.org/10.1002/pbc.23069

    Article  PubMed  Google Scholar 

  9. Zsiros J, Maibach R, Shafford E et al (2010) Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 28:2584–2590. https://doi.org/10.1200/JCO.2009.22.4857

    Article  CAS  PubMed  Google Scholar 

  10. Zsiros J, Brugieres L, Brock P et al (2013) Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol 14:834–842. https://doi.org/10.1016/S1470-2045(13)70272-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Katzenstein HM, Furman WL, Malogolowkin MH et al (2017) Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: a report from the Children’s Oncology Group AHEP0731 study committee: vincristine/irinotecan in hepatoblastoma. Cancer 123:2360–2367. https://doi.org/10.1002/cncr.30591

    Article  CAS  PubMed  Google Scholar 

  12. Malogolowkin MH, Katzenstein H, Krailo MD et al (2006) Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol Off J Am Soc Clin Oncol 24:2879–2884. https://doi.org/10.1200/JCO.2005.02.6013

    Article  CAS  Google Scholar 

  13. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, Jessup JM, Brierley JD, Gaspar LE, Schilsky RL, Balch CM, Winchester DP, Asare EA, Madera M, Gress DM, Meyer LR (2017) AJCC Cancer Staging Manual. Springer, Chicago

  14. Naus AJ, Borst A, Kuppens PS (1982) Determination of n-dimensional reference ellipsoids using patient data. J Clin Chem Clin Biochem Z Für Klin Chem Klin Biochem 20:75–80

    CAS  Google Scholar 

  15. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026

    Article  CAS  PubMed  Google Scholar 

  16. (2011) Base Sas 9.3 procedures guide. Sas Institute, Cary

  17. Katzenstein HM, London WB, Douglass EC et al (2002) Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. J Clin Oncol Off J Am Soc Clin Oncol 20:3438–3444

    Article  Google Scholar 

  18. Douglass EC, Reynolds M, Finegold M et al (1993) Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol Off J Am Soc Clin Oncol 11:96–99

    Article  CAS  Google Scholar 

  19. Ortega JA, Douglass EC, Feusner JH et al (2000) Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol Off J Am Soc Clin Oncol 18:2665–2675

    Article  CAS  Google Scholar 

  20. Katzenstein HM, Chang KW, Krailo M et al (2009) Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children’s Oncology Group. Cancer 115:5828–5835. https://doi.org/10.1002/cncr.24667

    Article  CAS  PubMed  Google Scholar 

  21. Casanova M, Massimino M, Ferrari A et al (2005) Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors. Pediatr Hematol Oncol 22:189–198. https://doi.org/10.1080/08880010590921441

    Article  CAS  PubMed  Google Scholar 

  22. Blohm ME, Vesterling-Hörner D, Calaminus G et al (1998) Alpha 1-fetoprotein (AFP) reference values in infants up to 2 years of age. Pediatr Hematol Oncol 15:135–142

    Article  CAS  PubMed  Google Scholar 

  23. Evans AE, Land VJ, Newton WA, et al (1982) Combination chemotherapy (vincristine, adriamycin, cyclophosphamide, and 5-fluorouracil) in the treatment of children with malignant hepatoma. Cancer 50:821–826. https://doi.org/10.1002/1097-0142(19820901)50:5<821::AID-CNCR2820500502>3.0.CO;2-K

    Article  CAS  PubMed  Google Scholar 

  24. von Schweinitz D, Byrd DJ, Hecker H et al (1997) Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Paediatric Liver Tumour Study HB89 of the German Society for Paediatric Oncology and Haematology. Eur J Cancer Oxf Engl 1990 33:1243–1249

    Google Scholar 

  25. Brown J, Perilongo G, Shafford E et al (2000) Pretreatment prognostic factors for children with hepatoblastoma—results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer Oxf Engl 1990 36:1418–1425

    CAS  Google Scholar 

  26. Pritchard J, Brown J, Shafford E et al (2000) Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach—results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol Off J Am Soc Clin Oncol 18:3819–3828

    Article  CAS  Google Scholar 

  27. Murphy AJ, Ayers GD, Hilmes MA et al (2013) Imaging analysis of hepatoblastoma resectability across neoadjuvant chemotherapy. J Pediatr Surg 48:1239–1248. https://doi.org/10.1016/j.jpedsurg.2013.03.019

    Article  PubMed  PubMed Central  Google Scholar 

  28. Medary I, Aronson D, Cheung NK et al (1996) Kinetics of primary tumor regression with chemotherapy: implications for the timing of surgery. Ann Surg Oncol 3:521–525

    Article  CAS  PubMed  Google Scholar 

  29. Muraoka A, Tokiwa T, Sato J (1989) Effects of chemotherapeutic agents on alpha-fetoprotein secretion and growth of human hepatoma cell lines in vitro. Br J Cancer 59:569–572

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Venkatramani R, Wang L, Malvar J et al (2012) Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma. Pediatr Blood Cancer 59:493–498. https://doi.org/10.1002/pbc.24038

    Article  PubMed  Google Scholar 

  31. Otte JB, Pritchard J, Aronson DC et al (2004) Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 42:74–83. https://doi.org/10.1002/pbc.10376

    Article  CAS  PubMed  Google Scholar 

  32. Howlander N, Noone A, Krapcho M et al (2011) SEER cancer statistics review, 1975–2009. National Cancer Institute, Bethesda

    Google Scholar 

Download references

Acknowledgements

Special thanks to Vani Shanker for editing the manuscript.

Author information

Authors and Affiliations

  1. Department of Oncology, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA

    Rosa Nguyen & Wayne L. Furman

  2. Department of Diagnostic Imaging, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA

    M. Beth McCarville

  3. Department of Biostatistics, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA

    April Sykes, Shenghua Mao & Jianrong Wu

  4. Department of Surgery, University of Tennessee Health Science Center, Le Bonheur Children’s Hospital, 50 N Dunlap St, Memphis, TN, 38105, USA

    Max R. Langham Jr.

Authors
  1. Rosa Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Beth McCarville
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. April Sykes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shenghua Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jianrong Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Max R. Langham Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wayne L. Furman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wayne L. Furman.

Ethics declarations

Conflict of interest

The authors have no conflict of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nguyen, R., McCarville, M.B., Sykes, A. et al. Rapid decrease of serum alpha-fetoprotein and tumor volume predicts outcome in children with hepatoblastoma treated with neoadjuvant chemotherapy. Int J Clin Oncol 23, 900–907 (2018). https://doi.org/10.1007/s10147-018-1285-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-018-1285-4

Keywords

Search

Navigation